(Q34658812)

English

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

scientific article published on 9 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Sergey Orlov

5

0 references

Igor N. Bondarenko

object named as

Igor Bondarenko

9

0 references

Maciej Krzakowski

object named as

Maciej Krzakowski

6

0 references

Jean-Yves Douillard

4

object named as

Jean-Yves Douillard

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

14

object named as

Silvia Novello

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Martin Reck

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Rolf Kaiser

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Anders Mellemgaard

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Joachim von Pawel

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Maya Gottfried

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Meilin Liao

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Claudia-Nanette Gann

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

José Barrueco

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Birgit Gaschler-Markefski

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

LUME-Lung 1 Study Group

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

9 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

143-155

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive genomic characterization of squamous cell lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The transcriptional landscape and mutational profile of lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

KIF5B-RET fusions in lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970586-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70586-2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34658812&oldid=2111277073"